Sanofi (SNYNF) Total Current Liabilities (2009 - 2025)
Sanofi (SNYNF) posted Total Current Liabilities of $33.0 billion for Q4 2025, little changed sequentially from $32.9 billion in Q2 2025, and up 5.88% YoY from $31.2 billion in Q4 2024.
Sanofi (SNYNF) Total Current Liabilities (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 17 years of Total Current Liabilities data on file, last reported at $33.0 billion in Q4 2025.
- Quarterly Total Current Liabilities rose 5.88% year-over-year to $33.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.0 billion (up 5.88% YoY) and the FY2025 annual result came in at $33.0 billion, up 5.88% from the prior year.
- Total Current Liabilities steadied at $33.0 billion in Q4 2025 per SNYNF's latest filing, from $32.9 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $33.0 billion in Q4 2025, with the low at $23.0 billion in Q2 2021.
- Average Total Current Liabilities over 5 years is $27.8 billion, with a median of $26.5 billion recorded in 2023.
- Year-over-year, Total Current Liabilities rose 0.4% in 2022 and advanced 19.93% in 2024.
- Sanofi's Total Current Liabilities stood at $24.4 billion in 2021, then rose by 0.4% to $24.5 billion in 2022, then climbed by 6.48% to $26.0 billion in 2023, then increased by 19.65% to $31.2 billion in 2024, then rose by 5.88% to $33.0 billion in 2025.
- Business Quant data shows SNYNF's Total Current Liabilities at $33.0 billion in Q4 2025, $32.9 billion in Q2 2025, and $31.2 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.99 Bn |
| Jun 30, 2025 | 32.89 Bn |
| Dec 31, 2024 | 31.16 Bn |
| Jun 30, 2024 | 32.34 Bn |
| Dec 31, 2023 | 26.05 Bn |
| Jun 30, 2023 | 26.96 Bn |
| Dec 31, 2022 | 24.46 Bn |
| Jun 30, 2022 | 23.54 Bn |
| Dec 31, 2021 | 24.36 Bn |
| Jun 30, 2021 | 23.03 Bn |
| Dec 31, 2020 | 22.95 Bn |
| Jun 30, 2020 | 20.71 Bn |
| Dec 31, 2019 | 345.90 Mn |
| Jun 30, 2019 | 21.58 Bn |
| Dec 31, 2018 | 19.83 Bn |
| Sep 30, 2018 | 251.24 Mn |
| Mar 31, 2018 | 22.78 Bn |
| Dec 31, 2017 | 18.21 Bn |
| Jun 30, 2017 | 18.75 Bn |
| Dec 31, 2016 | 17.75 Bn |